Location side image
Closing the gap on cancer

The Sarah Cannon Research Institute (SCRI) is a unique standalone trial facility that collaborates and works closely with clinical investigators to develop new and innovative cancer therapies, all whilst providing a premier patient experience.

Pushing innovation forward

As a dedicated trials unit open to both private and NHS patients, SCRI is focused on fast study set-ups to offer rapid access to new investigational drug therapies. Sarah Cannon Research Institute UK aims to provide precision medicine for cancer patients through the development of targeted therapies that are not only directed towards the cancer cell, but a specific alteration within the cancer cell. By joining our skilful medical team you’ll help provide a better future for all.